Publications by authors named "Purnima Pathak"

Claim this Profile
C
Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2- advanced breast cancer: a Medicare perspective.
Paolo Tarantino, Sarah Sammons, V K Gadi, Purnima Pathak, Gary Sopher

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.
Sarah Sammons, Paolo Tarantino, V K Gadi, Purnima Pathak, Gary Sopher

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Sarah Sammons, Denise A Yardley, Priyanka Sharma, Vijayakrishna K Gadi, Mark Pegram, Purnima Pathak

Oncol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer.
Joyce O'Shaughnessy, Sara M Tolaney, Denise A Yardley, Lowell Hart, Pedram Razavi, Purnima Pathak

Breast· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.
Victoria Harmer, Cathy Ammendolea, Mandy Ryan, Frances Boyle, Gustavo Werutsky, Purnima Pathak

Breast Care (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
Michael Untch, David Pérol, Erica L Mayer, Javier Cortes, Arnd Nusch, Purnima Pathak

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey.
Purnima Pathak, Leiyu Yue, Shaloo Gupta, Juanzhi Fang, M Andy Cheadle

Curr Med Res Opin· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer.
Komal Jhaveri, Joyce O'Shaughnessy, Peter A Fasching, Sara M Tolaney, Denise A Yardley, Purnima Pathak

Ther Adv Med Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.
Fatima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Purnima Pathak

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2- advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2.
David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana, Purnima Pathak

J Med Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison.
Hope S Rugo, Victoria Harmer, Joyce O'Shaughnessy, Komal Jhaveri, Sara M Tolaney, Purnima Pathak

Ther Adv Med Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil.
Anna Maria Buehler, Pierre-Alexandre Dionne, David Chandiwana, Purnima Pathak, Ebuwa Igho-Osagie

Rev Saude Publica· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and content validation of a self-completed, electronic Pediatric Asthma Symptom Diary.
Marci Clark, Carla Romano, Oyebimpe Olayinka-Amao, Diane Whalley, Rebecca Crawford, Purnima Pathak

J Patient Rep Outcomes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.
Debu Tripathy, Tristan Curteis, Sara Hurvitz, Denise Yardley, Fabio Franke, Purnima Pathak

Ther Adv Med Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis.
Leonhard Schaetz, Timo Rimner, Purnima Pathak, Juanzhi Fang, Deepak Chandrasekhar

Headache· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' perspectives on COPD: findings from a social media listening study.
Nigel S Cook, Konstantinos Kostikas, Jean-Bernard Gruenberger, Bhavik Shah, Purnima Pathak

ERJ Open Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Cibele Suzuki, Nilceia Lopes da Silva, Praveen Kumar, Purnima Pathak, Siew Hwa Ong

J Med Econ· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patents on brain permeable nanoparticles.
Monica Gulati, Dimple S Chopra, Sachin K Singh, Vikrant Saluja, Purnima Pathak

Recent Pat CNS Drug Discov· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain permeable nanoparticles.
Dimple Chopra, Monica Gulati, Vikrant Saluja, Purnima Pathak, Parikshit Bansal

Recent Pat CNS Drug Discov· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis